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Xfrom IR injury after pretreatment with A2AR agonists are
warranted. In addition, further study to more clearly define
the length of ischemic time that can be tolerated after pre-
treatment of donor lungs with ATL-1223 will be required
to define the full potential of this treatment strategy. It is
possible that treatment of donor lungs with ATL-1223
may allow for longer ischemic times than are currently ac-
ceptable after lung procurement, which ultimately may
serve to help redefine transplantation protocols in the not-
too-distant future.
CONCLUSIONS
Pretreatment of donor lungs with a bolus dose of A2AR
agonist proves efficacious and confers a similar level of pro-
tection from acute IR injury as other treatment strategies.
This pretreatment strategy could be easily implemented
into current, routine organ procurement protocols. A com-
bined treatment strategy with supplemental A2AR agonist
administration to the recipient during reperfusion may
provide additional attenuation of inflammation after trans-
plantation. These results support the development of phar-
macologic A2AR agonists for use in human clinical trials
to prevent acute graft failure after transplantation.
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Dr Patrick M. McCarthy (Chicago, Ill). That was a very clear
presentation. Is there work ongoing in other organs? The concern
would be about treating the lung donor if the effects on the other
organs are unknown.
Dr LaPar. That is a very pertinent question. An extensive
amount of work has been done with similar adenosine compounds
in other organ systems, such as the kidney and the liver, and these
investigations have demonstrated a significant benefit to using
these agonists. To my knowledge, the use of the ATL-1223 com-
pound as donor treatment in other organ systems has not been re-
ported. However, on the basis of this study, we are now beginning
experimental work with our other transplant colleagues to investi-
gate the potential benefits of such treatment in other organ
systems.rdiovascular Surgery c Volume 142, Number 4 893
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XDr J. William Gaynor (Philadelphia, Pa). Was any immuno-
suppression used in this model?
Dr LaPar. No.
Dr Gaynor. Are there any drug interactions of this agent with
the commonly used immunosuppressive agents? If you give
some other anti-inflammatory drug, such as a bolus of steroids,
will you see the same marked effect?
Dr LaPar. To my knowledge, there are no documented interac-
tions between immunosuppressive drugs such as steroids and some
of the other A2A agonists that we have used in the past, including
ATL-146e or ATL-313. As for ATL-1223, the pharmacokinetics
and drug interaction profiles are currently being investigated.
However, on the basis of what we know of the other compounds,
I would not anticipate any unforeseen negative interactions with
concomitant immunosuppressive therapy.
Dr Michael E. Jessen (Dallas, Tex). This is a very interesting
study. As you are moving toward clinical trials, I am concerned
that your model does not quite model what happens in the clinical
arena. Most donors have undergone some form of trauma or some894 The Journal of Thoracic and Cardiovascular Surgother event before organ procurement, which could incite the in-
flammatory response. Any time you are giving even a preoperative
dose of the drug, there actually may already be an inflammatory
response started. It sounded as though your protocol does not favor
brain death, either, the process of which also incites a lot of inflam-
matory cytokine response. Would you be wiser to look at some of
those scenarios before you take this to the clinical arena?
Dr LaPar. Thank you very much, Dr Jessen, for that question.
You bring up an important point that a donor setting after multiple
trauma or brain injury may be different from what we modeled in
the laboratory in this study. In these settings, it is widely known
that a profound inflammatory response is likely and that adenosine,
in general, has profound anti-inflammatory effects. Thus I believe
that even in these settings, provision of an agonist such as ATL-
1223 to the donor is going to confer a greater level of protection
than what can be achieved without it. I further believe that for
certain patients supplemental treatment to the recipient could be
beneficial to provide additional protection after establishing
reperfusion.ery c October 2011
